Remimazolam and Propofol Anesthesia in Elderly Patients
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Remimazolam is a recently developed ultra-short agonist acting at the benzodiazepine binding
site of the gamma-aminobutyric acid (GABA)A receptor. Remimazolam has a combination of the
hemodynamic stability of benzodiazepines and the advantages of propofol, such as rapid onset,
short duration of action, and improved controllability.
A recent study showed that the efficacy of two induction doses of remimazolam (6 and 12
mg/kg/h) as a sedative for general anesthesia was not inferior to propofol (2.0-2.5 mg/kg),
and hemodynamically more stable. On the other hand, a study on the emergence time and quality
between propofol and remimazolam showed inconsistent results.
The purpose of this study is to compare remimazolam to propofol on the intraoperative
hemodynamic changes and recovery profiles, when used in combination with remifentanil in
elderly patients undergoing general anesthesia.